Cancer Biopharmaceuticals
Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any ... Read More
1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Biologics 1.2.3 Biosimilars 1.3 Market by Application 1.3.1 Global Non-oncology Biopharmaceuticals Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Immunology 1.3.3 Endocrinology 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Non-oncology Biopharmaceuticals Market Perspective (2016-2027) 2.2 Non-oncology Biopharmaceuticals Growth Trends by Regions 2.2.1 Non-oncology Biopharmaceuticals Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Non-oncology Biopharmaceuticals Historic Market Share by Regions (2016-2021) 2.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Regions (2022-2027) 2.3 Non-oncology Biopharmaceuticals Industry Dynamic 2.3.1 Non-oncology Biopharmaceuticals Market Trends 2.3.2 Non-oncology Biopharmaceuticals Market Drivers 2.3.3 Non-oncology Biopharmaceuticals Market Challenges 2.3.4 Non-oncology Biopharmaceuticals Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue 3.1.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue (2016-2021) 3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2016-2021) 3.2 Global Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Non-oncology Biopharmaceuticals Revenue 3.4 Global Non-oncology Biopharmaceuticals Market Concentration Ratio 3.4.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Non-oncology Biopharmaceuticals Revenue in 2020 3.5 Non-oncology Biopharmaceuticals Key Players Head office and Area Served 3.6 Key Players Non-oncology Biopharmaceuticals Product Solution and Service 3.7 Date of Enter into Non-oncology Biopharmaceuticals Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Non-oncology Biopharmaceuticals Breakdown Data by Type 4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2016-2021) 4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2022-2027) 5 Non-oncology Biopharmaceuticals Breakdown Data by Application 5.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2016-2021) 5.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Non-oncology Biopharmaceuticals Market Size (2016-2027) 6.2 North America Non-oncology Biopharmaceuticals Market Size by Type 6.2.1 North America Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) 6.2.2 North America Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) 6.2.3 North America Non-oncology Biopharmaceuticals Market Size by Type (2016-2027) 6.3 North America Non-oncology Biopharmaceuticals Market Size by Application 6.3.1 North America Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) 6.3.2 North America Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) 6.3.3 North America Non-oncology Biopharmaceuticals Market Size by Application (2016-2027) 6.4 North America Non-oncology Biopharmaceuticals Market Size by Country 6.4.1 North America Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) 6.4.2 North America Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe Non-oncology Biopharmaceuticals Market Size (2016-2027) 7.2 Europe Non-oncology Biopharmaceuticals Market Size by Type 7.2.1 Europe Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) 7.2.2 Europe Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) 7.2.3 Europe Non-oncology Biopharmaceuticals Market Size by Type (2016-2027) 7.3 Europe Non-oncology Biopharmaceuticals Market Size by Application 7.3.1 Europe Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) 7.3.2 Europe Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) 7.3.3 Europe Non-oncology Biopharmaceuticals Market Size by Application (2016-2027) 7.4 Europe Non-oncology Biopharmaceuticals Market Size by Country 7.4.1 Europe Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) 7.4.2 Europe Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size (2016-2027) 8.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type 8.2.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2016-2027) 8.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application 8.3.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2016-2027) 8.4 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region 8.4.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Non-oncology Biopharmaceuticals Market Size (2016-2027) 9.2 Latin America Non-oncology Biopharmaceuticals Market Size by Type 9.2.1 Latin America Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) 9.2.2 Latin America Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) 9.2.3 Latin America Non-oncology Biopharmaceuticals Market Size by Type (2016-2027) 9.3 Latin America Non-oncology Biopharmaceuticals Market Size by Application 9.3.1 Latin America Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) 9.3.2 Latin America Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) 9.3.3 Latin America Non-oncology Biopharmaceuticals Market Size by Application (2016-2027) 9.4 Latin America Non-oncology Biopharmaceuticals Market Size by Country 9.4.1 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) 9.4.2 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size (2016-2027) 10.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type 10.2.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2016-2027) 10.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application 10.3.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2016-2027) 10.4 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country 10.4.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Roche 11.1.1 Roche Company Details 11.1.2 Roche Business Overview 11.1.3 Roche Non-oncology Biopharmaceuticals Introduction 11.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.1.5 Roche Recent Development 11.2 Sanofi 11.2.1 Sanofi Company Details 11.2.2 Sanofi Business Overview 11.2.3 Sanofi Non-oncology Biopharmaceuticals Introduction 11.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.2.5 Sanofi Recent Development 11.3 Johnson & Johnson 11.3.1 Johnson & Johnson Company Details 11.3.2 Johnson & Johnson Business Overview 11.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Introduction 11.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.3.5 Johnson & Johnson Recent Development 11.4 Pfizer 11.4.1 Pfizer Company Details 11.4.2 Pfizer Business Overview 11.4.3 Pfizer Non-oncology Biopharmaceuticals Introduction 11.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.4.5 Pfizer Recent Development 11.5 Novo Nordisk 11.5.1 Novo Nordisk Company Details 11.5.2 Novo Nordisk Business Overview 11.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Introduction 11.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.5.5 Novo Nordisk Recent Development 11.6 Novartis 11.6.1 Novartis Company Details 11.6.2 Novartis Business Overview 11.6.3 Novartis Non-oncology Biopharmaceuticals Introduction 11.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.6.5 Novartis Recent Development 11.7 Merck 11.7.1 Merck Company Details 11.7.2 Merck Business Overview 11.7.3 Merck Non-oncology Biopharmaceuticals Introduction 11.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.7.5 Merck Recent Development 11.8 Teva 11.8.1 Teva Company Details 11.8.2 Teva Business Overview 11.8.3 Teva Non-oncology Biopharmaceuticals Introduction 11.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.8.5 Teva Recent Development 11.9 Eli Lilly 11.9.1 Eli Lilly Company Details 11.9.2 Eli Lilly Business Overview 11.9.3 Eli Lilly Non-oncology Biopharmaceuticals Introduction 11.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.9.5 Eli Lilly Recent Development 11.10 Bristol-Myers Squibb 11.10.1 Bristol-Myers Squibb Company Details 11.10.2 Bristol-Myers Squibb Business Overview 11.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Introduction 11.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.10.5 Bristol-Myers Squibb Recent Development 11.11 GlaxoSmithKline 11.11.1 GlaxoSmithKline Company Details 11.11.2 GlaxoSmithKline Business Overview 11.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Introduction 11.11.4 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.11.5 GlaxoSmithKline Recent Development 11.12 UCB Pharma 11.12.1 UCB Pharma Company Details 11.12.2 UCB Pharma Business Overview 11.12.3 UCB Pharma Non-oncology Biopharmaceuticals Introduction 11.12.4 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.12.5 UCB Pharma Recent Development 11.13 Amgen 11.13.1 Amgen Company Details 11.13.2 Amgen Business Overview 11.13.3 Amgen Non-oncology Biopharmaceuticals Introduction 11.13.4 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.13.5 Amgen Recent Development 11.14 AbbVie 11.14.1 AbbVie Company Details 11.14.2 AbbVie Business Overview 11.14.3 AbbVie Non-oncology Biopharmaceuticals Introduction 11.14.4 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.14.5 AbbVie Recent Development 11.15 Takeda 11.15.1 Takeda Company Details 11.15.2 Takeda Business Overview 11.15.3 Takeda Non-oncology Biopharmaceuticals Introduction 11.15.4 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.15.5 Takeda Recent Development 11.16 AstraZeneca 11.16.1 AstraZeneca Company Details 11.16.2 AstraZeneca Business Overview 11.16.3 AstraZeneca Non-oncology Biopharmaceuticals Introduction 11.16.4 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.16.5 AstraZeneca Recent Development 11.17 Mylan 11.17.1 Mylan Company Details 11.17.2 Mylan Business Overview 11.17.3 Mylan Non-oncology Biopharmaceuticals Introduction 11.17.4 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.17.5 Mylan Recent Development 11.18 LEO Pharma 11.18.1 LEO Pharma Company Details 11.18.2 LEO Pharma Business Overview 11.18.3 LEO Pharma Non-oncology Biopharmaceuticals Introduction 11.18.4 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.18.5 LEO Pharma Recent Development 11.18 Boehringer Ingelheim .1 Boehringer Ingelheim Company Details .2 Boehringer Ingelheim Business Overview .3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Introduction .4 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) .5 Boehringer Ingelheim Recent Development 11.20 Alexion Pharmaceuticals 11.20.1 Alexion Pharmaceuticals Company Details 11.20.2 Alexion Pharmaceuticals Business Overview 11.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Introduction 11.20.4 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.20.5 Alexion Pharmaceuticals Recent Development 11.21 Elusys Therapeutics 11.21.1 Elusys Therapeutics Company Details 11.21.2 Elusys Therapeutics Business Overview 11.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Introduction 11.21.4 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.21.5 Elusys Therapeutics Recent Development 11.22 Swedish Orphan Biovitrum 11.22.1 Swedish Orphan Biovitrum Company Details 11.22.2 Swedish Orphan Biovitrum Business Overview 11.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Introduction 11.22.4 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.22.5 Swedish Orphan Biovitrum Recent Development 11.23 Biogen 11.23.1 Biogen Company Details 11.23.2 Biogen Business Overview 11.23.3 Biogen Non-oncology Biopharmaceuticals Introduction 11.23.4 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) 11.23.5 Biogen Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details
List of Tables Table 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Biologics Table 3. Key Players of Biosimilars Table 4. Global Non-oncology Biopharmaceuticals Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 5. Global Non-oncology Biopharmaceuticals Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 6. Global Non-oncology Biopharmaceuticals Market Size by Regions (2016-2021) & (US$ Million) Table 7. Global Non-oncology Biopharmaceuticals Market Share by Regions (2016-2021) Table 8. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 9. Global Non-oncology Biopharmaceuticals Market Share by Regions (2022-2027) Table 10. Non-oncology Biopharmaceuticals Market Trends Table 11. Non-oncology Biopharmaceuticals Market Drivers Table 12. Non-oncology Biopharmaceuticals Market Challenges Table 13. Non-oncology Biopharmaceuticals Market Restraints Table 14. Global Non-oncology Biopharmaceuticals Revenue by Players (2016-2021) & (US$ Million) Table 15. Global Non-oncology Biopharmaceuticals Market Share by Players (2016-2021) Table 16. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-oncology Biopharmaceuticals as of 2020) Table 17. Ranking of Global Top Non-oncology Biopharmaceuticals Companies by Revenue (US$ Million) in 2020 Table 18. Global 5 Largest Players Market Share by Non-oncology Biopharmaceuticals Revenue (CR5 and HHI) & (2016-2021) Table 19. Key Players Headquarters and Area Served Table 20. Key Players Non-oncology Biopharmaceuticals Product Solution and Service Table 21. Date of Enter into Non-oncology Biopharmaceuticals Market Table 22. Mergers & Acquisitions, Expansion Plans Table 23. Global Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million) Table 24. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2016-2021) Table 25. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2022-2027) (US$ Million) Table 26. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2022-2027) & (US$ Million) Table 27. Global Non-oncology Biopharmaceuticals Market Size Share by Application (2016-2021) & (US$ Million) Table 28. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2016-2021) Table 29. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2022-2027) (US$ Million) Table 30. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2022-2027) & (US$ Million) Table 31. North America Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million) Table 32. North America Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million) Table 33. North America Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million) Table 34. North America Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million) Table 35. North America Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million) Table 36. North America Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million) Table 37. Europe Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million) Table 38. Europe Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million) Table 39. Europe Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million) Table 40. Europe Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million) Table 41. Europe Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million) Table 42. Europe Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million) Table 43. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million) Table 44. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million) Table 45. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million) Table 46. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million) Table 47. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2016-2021) & (US$ Million) Table 48. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2022-2027) & (US$ Million) Table 49. Latin America Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million) Table 50. Latin America Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million) Table 51. Latin America Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million) Table 52. Latin America Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million) Table 53. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million) Table 54. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million) Table 55. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2016-2021) (US$ Million) Table 56. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2022-2027) & (US$ Million) Table 57. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2016-2021) (US$ Million) Table 58. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2022-2027) & (US$ Million) Table 59. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2016-2021) & (US$ Million) Table 60. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2022-2027) & (US$ Million) Table 61. Roche Company Details Table 62. Roche Business Overview Table 63. Roche Non-oncology Biopharmaceuticals Product Table 64. Roche Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 65. Roche Recent Development Table 66. Sanofi Company Details Table 67. Sanofi Business Overview Table 68. Sanofi Non-oncology Biopharmaceuticals Product Table 69. Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 70. Sanofi Recent Development Table 71. Johnson & Johnson Company Details Table 72. Johnson & Johnson Business Overview Table 73. Johnson & Johnson Non-oncology Biopharmaceuticals Product Table 74. Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 75. Johnson & Johnson Recent Development Table 76. Pfizer Company Details Table 77. Pfizer Business Overview Table 78. Pfizer Non-oncology Biopharmaceuticals Product Table 79. Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 80. Pfizer Recent Development Table 81. Novo Nordisk Company Details Table 82. Novo Nordisk Business Overview Table 83. Novo Nordisk Non-oncology Biopharmaceuticals Product Table 84. Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 85. Novo Nordisk Recent Development Table 86. Novartis Company Details Table 87. Novartis Business Overview Table 88. Novartis Non-oncology Biopharmaceuticals Product Table 89. Novartis Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 90. Novartis Recent Development Table 91. Merck Company Details Table 92. Merck Business Overview Table 93. Merck Non-oncology Biopharmaceuticals Product Table 94. Merck Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 95. Merck Recent Development Table 96. Teva Company Details Table 97. Teva Business Overview Table 98. Teva Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 99. Teva Recent Development Table 100. Eli Lilly Company Details Table 101. Eli Lilly Business Overview Table 102. Eli Lilly Non-oncology Biopharmaceuticals Product Table 103. Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 104. Eli Lilly Recent Development Table 105. Bristol-Myers Squibb Company Details Table 106. Bristol-Myers Squibb Business Overview Table 107. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product Table 108. Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 109. Bristol-Myers Squibb Recent Development Table 110. GlaxoSmithKline Company Details Table 111. GlaxoSmithKline Business Overview Table 112. GlaxoSmithKline Non-oncology Biopharmaceuticals Product Table 113. GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 114. GlaxoSmithKline Recent Development Table 115. UCB Pharma Company Details Table 116. UCB Pharma Business Overview Table 117. UCB Pharma Non-oncology Biopharmaceuticals Product Table 118. UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 119. UCB Pharma Recent Development Table 120. Amgen Company Details Table 121. Amgen Business Overview Table 122. Amgen Non-oncology Biopharmaceuticals Product Table 123. Amgen Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 124. Amgen Recent Development Table 125. AbbVie Company Details Table 126. AbbVie Business Overview Table 127. AbbVie Non-oncology Biopharmaceuticals Product Table 128. AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 129. AbbVie Recent Development Table 130. Takeda Company Details Table 131. Takeda Business Overview Table 132. Takeda Non-oncology Biopharmaceuticals Product Table 133. Takeda Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 134. Takeda Recent Development Table 135. AstraZeneca Company Details Table 136. AstraZeneca Business Overview Table 137. AstraZeneca Non-oncology Biopharmaceuticals Product Table 138. AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 139. AstraZeneca Recent Development Table 140. Mylan Company Details Table 141. Mylan Business Overview Table 142. Mylan Non-oncology Biopharmaceuticals Product Table 143. Mylan Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 144. Mylan Recent Development Table 145. LEO Pharma Company Details Table 146. LEO Pharma Business Overview Table 147. LEO Pharma Non-oncology Biopharmaceuticals Product Table 148. LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 149. LEO Pharma Recent Development Table 150. Boehringer Ingelheim Company Details Table 151. Boehringer Ingelheim Business Overview Table 152. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product Table 153. Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 154. Boehringer Ingelheim Recent Development Table 155. Alexion Pharmaceuticals Company Details Table 156. Alexion Pharmaceuticals Business Overview Table 157. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product Table 158. Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 159. Alexion Pharmaceuticals Recent Development Table 160. Elusys Therapeutics Company Details Table 161. Elusys Therapeutics Business Overview Table 162. Elusys Therapeutics Non-oncology Biopharmaceuticals Product Table 163. Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 164. Elusys Therapeutics Recent Development Table 165. Swedish Orphan Biovitrum Company Details Table 166. Swedish Orphan Biovitrum Business Overview Table 167. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product Table 168. Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 169. Swedish Orphan Biovitrum Recent Development Table 170. Biogen Company Details Table 171. Biogen Business Overview Table 172. Biogen Non-oncology Biopharmaceuticals Product Table 173. Biogen Revenue in Non-oncology Biopharmaceuticals Business (2016-2021) & (US$ Million) Table 174. Biogen Recent Development Table 175. Research Programs/Design for This Report Table 176. Key Data Information from Secondary Sources Table 177. Key Data Information from Primary Sources List of Figures Figure 1. Global Non-oncology Biopharmaceuticals Market Share by Type: 2020 VS 2027 Figure 2. Biologics Features Figure 3. Biosimilars Features Figure 4. Global Non-oncology Biopharmaceuticals Market Share by Application: 2020 VS 2027 Figure 5. Immunology Case Studies Figure 6. Endocrinology Case Studies Figure 7. Others Case Studies Figure 8. Non-oncology Biopharmaceuticals Report Years Considered Figure 9. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 10. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 11. Global Non-oncology Biopharmaceuticals Market Share by Regions: 2020 VS 2027 Figure 12. Global Non-oncology Biopharmaceuticals Market Share by Regions (2022-2027) Figure 13. Global Non-oncology Biopharmaceuticals Market Share by Players in 2020 Figure 14. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-oncology Biopharmaceuticals as of 2020 Figure 15. The Top 10 and 5 Players Market Share by Non-oncology Biopharmaceuticals Revenue in 2020 Figure 16. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2016-2021) Figure 17. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2022-2027) Figure 18. North America Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 19. North America Non-oncology Biopharmaceuticals Market Share by Type (2016-2027) Figure 20. North America Non-oncology Biopharmaceuticals Market Share by Application (2016-2027) Figure 21. North America Non-oncology Biopharmaceuticals Market Share by Country (2016-2027) Figure 22. United States Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 23. Canada Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 24. Europe Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 25. Europe Non-oncology Biopharmaceuticals Market Share by Type (2016-2027) Figure 26. Europe Non-oncology Biopharmaceuticals Market Share by Application (2016-2027) Figure 27. Europe Non-oncology Biopharmaceuticals Market Share by Country (2016-2027) Figure 28. Germany Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 29. France Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 30. U.K. Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 31. Italy Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 32. Russia Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 33. Nordic Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. Asia-Pacific Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Type (2016-2027) Figure 36. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Application (2016-2027) Figure 37. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Region (2016-2027) Figure 38. China Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 39. Japan Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. South Korea Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 41. Southeast Asia Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 42. India Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 43. Australia Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. Latin America Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. Latin America Non-oncology Biopharmaceuticals Market Share by Type (2016-2027) Figure 46. Latin America Non-oncology Biopharmaceuticals Market Share by Application (2016-2027) Figure 47. Latin America Non-oncology Biopharmaceuticals Market Share by Country (2016-2027) Figure 48. Mexico Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 49. Brazil Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Middle East & Africa Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 51. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Type (2016-2027) Figure 52. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Application (2016-2027) Figure 53. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Country (2016-2027) Figure 54. Turkey Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 55. Saudi Arabia Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 56. UAE Non-oncology Biopharmaceuticals Market Size YoY Growth (2016-2027) & (US$ Million) Figure 57. Roche Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 58. Sanofi Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 59. Johnson & Johnson Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 60. Pfizer Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 61. Novo Nordisk Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 62. Novartis Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 63. Merck Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 64. Teva Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 65. Eli Lilly Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 66. Bristol-Myers Squibb Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 67. GlaxoSmithKline Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 68. UCB Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 69. Amgen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 70. AbbVie Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 71. Takeda Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 72. AstraZeneca Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 73. Mylan Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 74. LEO Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 75. Boehringer Ingelheim Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 76. Alexion Pharmaceuticals Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 77. Elusys Therapeutics Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 78. Swedish Orphan Biovitrum Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 79. Biogen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2016-2021) Figure 80. Bottom-up and Top-down Approaches for This Report Figure 81. Data Triangulation Figure 82. Key Executives Interviewed
Roche Sanofi Johnson & Johnson Pfizer Novo Nordisk Novartis Merck Teva Eli Lilly Bristol-Myers Squibb GlaxoSmithKline UCB Pharma Amgen AbbVie Takeda AstraZeneca Mylan LEO Pharma Boehringer Ingelheim Alexion Pharmaceuticals Elusys Therapeutics Swedish Orphan Biovitrum Biogen
Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any ... Read More
Accounting Practice Management software is a solution for tax, audit, accounting or bookkeeping s ... Read More
Supply Chain Risk Management (SCRM)
Market Analysis and Insights: Gl ... Read More
P2X7 Receptor (P2X7R) is an ATP-gated ion channel primarily expressed on cells of the immune syst ... Read More